Cargando…

Chemo-Immunotherapy: A New Trend in Cancer Treatment

SIMPLE SUMMARY: Chemoimmunotherapy is an emerging treatment option for cancer that combines traditional chemotherapy with immunotherapy. This approach aims to increase the efficacy of cancer treatment by simultaneously targeting cancer cells through chemotherapy and boosting the immune system’s abil...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sordo-Bahamonde, Christian, Lorenzo-Herrero, Seila, Gonzalez-Rodriguez, Ana P., Martínez-Pérez, Alejandra, Rodrigo, Juan P., García-Pedrero, Juana M., Gonzalez, Segundo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10252089/ https://www.ncbi.nlm.nih.gov/pubmed/37296876 http://dx.doi.org/10.3390/cancers15112912

Ejemplares similares

Beyond the anti-PD-1/PD-L1 era: promising role of the BTLA/HVEM axis as a future target for cancer immunotherapy
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2023)

NK Cell-Based Immunotherapy in Cancer Metastasis
por: Lorenzo-Herrero, Seila, et al.
Publicado: (2018)

Mechanisms of Resistance to NK Cell Immunotherapy
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2020)

NK Cells in the Treatment of Hematological Malignancies
por: Gonzalez-Rodriguez, Ana P, et al.
Publicado: (2019)

Immunosurveillance of cancer cell stress
por: Lorenzo-Herrero, Seila, et al.
Publicado: (2019)

BTLA/HVEM Axis Induces NK Cell Immunosuppression and Poor Outcome in Chronic Lymphocytic Leukemia
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2021)

LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2021)

Mechanisms of Apoptosis Resistance to NK Cell-Mediated Cytotoxicity in Cancer
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2020)

BTLA dysregulation correlates with poor outcome and diminished T cell-mediated antitumor responses in chronic lymphocytic leukemia
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2023)

Immunoglobulin‐like transcript 2 blockade restores antitumor immune responses in glioblastoma
por: Lorenzo‐Herrero, Seila, et al.
Publicado: (2022)

Ig-Like Transcript 2 (ILT2) Blockade and Lenalidomide Restore NK Cell Function in Chronic Lymphocytic Leukemia
por: Villa-Álvarez, Mónica, et al.
Publicado: (2018)

Driver Mutations and Single Copy Number Abnormalities Identify Binet Stage A Patients with Chronic Lymphocytic Leukemia with Aggressive Progression
por: Gonzalez-Rodriguez, Ana P., et al.
Publicado: (2020)

The Mithralog EC-7072 Induces Chronic Lymphocytic Leukemia Cell Death by Targeting Tonic B-Cell Receptor Signaling
por: Lorenzo-Herrero, Seila, et al.
Publicado: (2019)

Lectin-Like Transcript 1 (LLT1) Checkpoint: A Novel Independent Prognostic Factor in HPV-Negative Oropharyngeal Squamous Cell Carcinoma
por: Sanchez-Canteli, Mario, et al.
Publicado: (2020)

Bcl-2 Inhibition to Overcome Resistance to Chemo- and Immunotherapy
por: García-Aranda, Marilina, et al.
Publicado: (2018)

Cystatin C-Based Equations Detect Hidden Kidney Disease and Poor Prognosis in Newly Diagnosed Patients with Multiple Myeloma
por: Cepeda-Piorno, Francisco-Javier, et al.
Publicado: (2022)

Podoplanin expression in the development and progression of laryngeal squamous cell carcinomas
por: Rodrigo, Juan P, et al.
Publicado: (2010)

The Emerging Role of NK Cells in Immune Checkpoint Blockade
por: Martinez-Perez, Alejandra, et al.
Publicado: (2022)

The need to optimize chemotherapy regimens for chemo-immunotherapy
por: Inamura, Kentaro, et al.
Publicado: (2022)

Dramatic response of metaplastic breast cancer to chemo-immunotherapy
por: Adams, Sylvia
Publicado: (2017)

A mathematical model for treatment using chemo-immunotherapy
por: Nave, Ophir
Publicado: (2022)

Study of the Interactions Between Bacteriophage phiIPLA-RODI and Four Chemical Disinfectants for the Elimination of Staphylococcus aureus Contamination
por: Agún, Seila, et al.
Publicado: (2018)

Stabilization of p21 by mTORC1/4E-BP1 predicts clinical outcome of head and neck cancers
por: Llanos, Susana, et al.
Publicado: (2016)

Targeting Key Signaling Pathways in Glioblastoma Stem Cells for the Development of Efficient Chemo- and Immunotherapy
por: Helweg, Laureen P., et al.
Publicado: (2022)

Chemo-Immunotherapy with Oxaliplatin and Interleukin-7 Inhibits Colon Cancer Metastasis in Mice
por: Gou, Hong-Feng, et al.
Publicado: (2014)

Lymphocyte function and response to chemo-immunotherapy in patients with metastatic melanoma.
por: Thatcher, N., et al.
Publicado: (1977)

Nanoparticle-enhanced chemo-immunotherapy to trigger robust antitumor immunity
por: Liang, Jingjing, et al.
Publicado: (2020)

Two types of biomarker-dependent chemo-immunotherapy for pancreatic cancer?
por: Melief, Cornelis J.M.
Publicado: (2022)

Senescence induction dictates response to chemo- and immunotherapy in preclinical models of ovarian cancer
por: Paffenholz, Stella V., et al.
Publicado: (2022)

The Emerging Role of NANOG as an Early Cancer Risk Biomarker in Patients with Oral Potentially Malignant Disorders
por: de Vicente, Juan C., et al.
Publicado: (2019)

To Chemo or Not to Chemo… That Is the Question
por: Martin, Maria Felisa Eva B., et al.
Publicado: (2023)

A Comparison Between Chemo-Radiotherapy Combined With Immunotherapy and Chemo-Radiotherapy Alone for the Treatment of Newly Diagnosed Glioblastoma: A Systematic Review and Meta-Analysis
por: Lara-Velazquez, Montserrat, et al.
Publicado: (2021)

Exploiting metabolic inhibition to eradicate residual tumors after chemo-immunotherapy
por: Habtetsion, Tsadik, et al.
Publicado: (2014)

Chemo-Immunotherapy Using Lentinan for the Treatment of Gastric Cancer with Liver Metastases
por: Ina, Kenji, et al.
Publicado: (2016)

Chemo-immunotherapy for Older Patients with Chronic Lymphocytic Leukemia – Time to Retire?
por: Scarfò, Lydia, et al.
Publicado: (2019)

Chemo-immunotherapy for Older Patients with Chronic Lymphocytic Leukemia – Passé Yet?
por: Danilov, Alexey V., et al.
Publicado: (2019)

Chemo-immunotherapy as first-line treatment for small-cell lung cancer
por: Farid, Saira, et al.
Publicado: (2020)

Controversies in NSCLC: which second-line strategy after chemo-immunotherapy?
por: Moliner, L., et al.
Publicado: (2023)

Dual Synergistic Tumor‐Specific Polymeric Nanoparticles for Efficient Chemo‐Immunotherapy
por: Xiang, Jiajia, et al.
Publicado: (2023)

Neoadjuvant chemo-immunotherapy for lung cancer: how much is too much?
por: Deboever, Nathaniel, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_righrm3bf1g8nvkt6li59joslt